GILD
Gilead Sciences, Inc.
- Total liabilities, 2025
- $36.4B
- YoY, 2025
- −8.4%
- 5-year CAGR
- −6.2%
- 10-year CAGR
- +1.1%
Total liabilities
Total liabilities by fiscal year
| Period | Total liabilities | YoY |
|---|---|---|
| 2025 | $36.4B | −8.4% |
| 2024 | $39.7B | +0.9% |
| 2023 | $39.4B | −6.2% |
| 2022 | $42.0B | −10.5% |
| 2021 | $46.9B | −6.6% |
| 2020 | $50.2B | +28.8% |
| 2019 | $39.0B | −7.5% |
| 2018 | $42.1B | −15.3% |
| 2017 | $49.8B | +32.3% |
| 2016 | $37.6B | +15.4% |
| 2015 | $32.6B | +73.1% |
| 2014 | $18.8B | +74.8% |
| 2013 | $10.8B | −7.9% |
| 2012 | $11.7B | +12.0% |
| 2011 | $10.4B | +90.8% |
| 2010 | $5.5B | +71.3% |
| 2009 | $3.2B | +29.2% |
| 2008 | $2.5B | — |